|
1kit (10Vial) .
| Ɔmɔs: | |
|---|---|
▎ Risach we dɛn kɔl Retatrutid
Wetin na di risach bakgrɔn fɔ Retatrutid?
Fat pasmak dɔn bi wan pan di big big pɔblik wɛlbɔdi prɔblɛm dɛn na di sosayti tide. I kin mek yu gɛt bɔku bɔku wɛlbɔdi prɔblɛm dɛn lɛk tayp 2 dayabitis, sik dɛn we de mek yu at ɛn blɔd, ay blɔd prɛshɔn, dislipidemia, ɛn fat liva sik we nɔ de drink rɔm. Wit di kɔntinyu we di pipul dɛn we fat de bɔku, dɛn de nid fɔ gɛt nyu tritmɛnt dɛn we go ebul fɔ manej di bɔdi wet fayn fayn wan ɛn mek di wɛlbɔdi kɔndishɔn bɛtɛ [1] . Pan ɔl we di tin dɛn we pɔsin kin du fɔ liv in layf, lɛk fɔ mek i ebul fɔ du mɔ ɛn fɔ kɔntrol di it we i de it, na di men tin dɛn we dɛn kin du fɔ mek dɛn ebul fɔ kɔntrol dɛn wet, i rili at fɔ mek bɔku big pipul dɛn we fat pasmak fɔ mek dɛn kɔntinyu fɔ lɔs dɛn wet fɔ lɔng tɛm.
rεtatrutid, as nכvel tripl rεsεpכta agonist, kin akt pan di glukagכn lεk pεptida-1 rεsεpכta (
GLP-1R), glukכs-dipεndεnt insulinotropik pכlipεptida rεsεptכr (GIPR), εn glukכgכn rεsεptכr (GCGR). dis mכlti-rεsεptor mεkanism fכ akshכn de εndow am wit signifyant advantej dεm na di fil fכ lכs weit. we yu kכmpεr wit di weit lכs dכg dεm we de akt pan wan rεsεptכr nכmכ, Retatrutid kin mכr kכmprεhεnsiv rεgεl di bכdi in mεtabolik prכsεs dεm [1] . Retatrutid de ajɔst di wet we i de lɔs bay we i de rigul bɔku ɔmon rεsεpכta dεm, nכ de sho se i de sho se i de wok fayn bכt i de gεt rεlatεvli mild gεstrointestinal sayd ifekt dεm. apat frכm dat, as tripl rεsεptכr agonist, Retatrutid gεt mכr pawaful weit lכs ifekt εn wan big rεnj כf aplikεbl populeshכn kכmpεr wit כda nyu weit lכs drog dεm.
Wetin na Retatrutid?
Retatrutid na nכvel lכng-akt glukagכn lεk pεptida-1 (GLP-1) rεsεptכr agonist. i de modify εn optimiz bays pan di strכkchכ fכ nεchכral GLP-1, εn i kin spεshal biεn εn aktibכt di GLP-1 rεsεpכta, εksεrt fysiolojikal fכnshכn dεm we sכm kayn we lεk di nεchכral GLP-1, lεk fכ promuot insulin sekreshכn, inhibit glukagon sekreshכn, delay gastric εmpti, rεdכks apεtit, εtk I gεt brayt aplikεshכn prכspεkt in di tritmεnt fכ dayabitis εn wet mεnejmεnt.
Wetin na di mɛkanism fɔ akshɔn fɔ Retatrutid?
di mεkanism fכ akshכn fכ Retatrutid kכmכt frכm in agonistik ifekt dεm pan mכltipכl rεsεpכta dεm. fכs, in agonistik ifekt pan di glukagon lεk pεptida-1 rεsεpכta (GLP-1R) kin inkrεs insulin sekreshכn, inhibit glukagon sekreshכn, lכs di blכd glukכs lεvεl, εn di sem tεm de delay gastric εmpti, inkrεs satiety, εn ridyus it intake [2] . sεkכn, in agonistik ifekt pan di glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta (GIPR) kin promuot insulin sekreshכn, εnhans glukכs yutilizeshכn, εn afekt fεt mεtabolism, inhεbit lipolysis εn promuot fεt sεntesis [2] . pan tap dat, di agonistik ifekt we Retatrutid de gi pan di glukagon rεsεpכta (GCGR) kin כlwayz fכ protεkt glycogenolysis εn gluconeogenesis insay di liva, we de inkrεs di bכdi glukכs lεvεl. כl di akshכn fכ Retatrutid, dis glukכs-rayzin ifekt de כfset bay di ifekt dεm we di כda tu rεsεpכta dεm de gi, we i de protεkt lipolysis εn ridyus fεt akyumyuleshכn [2] . dis mכlti-target mכd fכ akshכn kin bi mכr ifektiv fכ trit fכ fat pas singl rεsεptכr agonist dεm.
bay we i de aktibכt dεn tri rεsεpכta dεm ya wan tεm, Retatrutid kin εksyεrt difrεn mεtabolik rεgεdyushכn ifekt dεm εn prodyuz tεrapi ifekt pan fכ fat εn sik dεm we de kכmכt wit am. pan tεm fכ rεgεl di blכd glukכs lεvεl, biכs di aktibכshכn fכ GLP-1R εn GIPR de protεkt insulin sekreshכn εn inhεbit glukagon sekreshכn, εn di aktibכshכn fכ GCGR de כfset bay di ifekt dεm we di כda tu rεsεpכta dεm de gi, Retatrutid kin rigul di blכd glukכs lεvεl fayn fayn wan, we na big minin fכ di tritmεnt fכ tayp 2 dayabεtis mεllitus [1, 2] . pan tεm fכ ridyus fεt akyumyuleshכn, di aktibכshכn fכ GCGR de promuot lipolysis εn ridyus fεt akyumyuleshכn, we di aktibכshכn fכ GLP-1R de inkrεs satiety εn ridyus fכd intake, we de ridyus fεt sεntesis mכr [1] . Apat frɔm dat, Retatrutid gɛt impɔtant ifɛkt bak pan di sik we nɔ gɛt rɔm we gɛt fat liva. I kin mek di fat we de insay di liva nɔ bɔku ɛn i kin mek di liva wok fayn.
HbA1c, bɔdi wet, blɔd prɛshɔn, ɛn lipid dɛn Data na lɛst-skwea min (wit mistek bar dɛn we de sho SE dɛn) frɔm di ɛfifikɛshɔn analisis sɛt, pas nɔmɔ dɛn no ɔda we.
Sos:PubMed [4] we dɛn pul am.
Insay us aspek dɛn Retatrutid de sho in ifɛkt dɛn?
Retatrutid de sho signifyant ifekt in mכltipכl aspek dεm
Signifikant weit loss ifekt: Retatrutid don sho signifikant weit loss ifekt in mכltipכl klinik trial dεm. Fɔ ɛgzampul, insay wan klinik stɔdi we involv 338 big pipul dɛn (Jastreboff AMM, 2023), pasɛnt dɛn we dɛn trit wit difrɛn dos dɛn fɔ Retatrutid bin gɛt bɔku bɔku wet lɔs we dɛn ol 48 wik. Na dɛn wan ya, di pasɛnt dɛn we bin de na di 12mg doz grup bin lɔs 24.2% pan dɛn bɔdi wet, ɛn wan ay prɔpɔshɔn pan di pasɛnt dɛn bin ajɔst di wet lɔs to difrɛn digri dɛn. Fɔ ɛgzampul, pan di pasɛnt dɛn we bin de tek 4mg, 8mg, ɛn 12mg dos, 92%, 100%, ɛn 100% pan di pasɛnt dɛn, rispɛktvɔli, bin lɔs 5% ɔ mɔ pan dɛn bɔdi wet. Insay wan ɔda stɔdi [3] , tu randomized kɔntrol trial we involv 353 pasɛnt dɛn we gɛt tayp 2 dayabitis mɛllitus sho se we yu kɔmpia am wit di plasɛbo, Retatrutid kin ridyus di bɔdi wet fɔ di pasɛnt dɛn bad bad wan bay 11.89kg, ɛn i kin ridyus bak di glycated hemoglobin (HbA1C). Apat frɔm dat, we dɛn bin de tray fɔ big pipul dɛn we fat we nɔ gɛt dayabitis, Retatrutid bin mek di sik pipul dɛn lɔs 24.2% pan dɛn wet, ɛn 83% pan di sik pipul dɛn bin lɔs 15% ɔ mɔ pan dɛn bɔdi wet we dɛn ol 48 wik. Dɛn rizɔlt ya sho se Retatrutid gɛt bɔku pawa fɔ lɔs yu wet.
Tritmɛnt fɔ tayp 2 dayabitis: Retatrutid de sho bak sɔm pɔtnɛshɛl fɔ trit tayp 2 dayabitis mɛlit. Insay sɔm klinik trayal dɛn, Retatrutid dɔn sho se di glycated hemoglobin (HbA1c) dɔn ridyus ɛn di wet we di pɔsin kin gɛt we i de du di doz. Fɔ ɛgzampul, insay wan stɔdi, pan pipul dɛn we gɛt tayp 2 dayabitis, Retatrutid sho se i gɛt bɔku pawa fɔ kɔntrol di glukɔs na dɛn blɔd. we yu kכmpεr wit di plasεbo, glycated hemoglobin dכn dכn bay 1.64% [3] . Apat frɔm dat, insay wan randomized, double-blind, placebo ɛn active-controlled parallel-group phase 2 trial, animal models wit tayp 2 dayabitis mellitus, afta dɛn dɔn gɛt Retatrutid tritmɛnt, sho se di glycated hemoglobin lɛvɛl dɔn go dɔŋ bad bad wan, ɛn dɛn bɔdi wet sɛf dɔn go dɔŋ insay wan we we dipen pan di doz [4] . dis kin bi fכ di kכmprεhεnsiv ifekt dεm we di dכg gεt pan GLP-1, GCGR, εn GIPR, we de impruv glukכs mεtabolism εn εnεji bεlε.
di impruvment fכ di kכdivaskyul risk fכktכ dεm: Retatrutid nכ kin כnli ridyus di bכdi wet bכt i kin impruv di kכdivaskyul risk fכktכ dεm, lεk di sεrum lipid profayl εn di glycated hemoglobin lεvεl. Dis de sho se wan klos pathophysiological link de bitwin fat ɛn kadyovaskyuɛl sik dɛm, ɛn Retatrutid kin impruv di kadyovaskyuɛl wɛlbɔdi fɔ di wan dɛm we fat pasmak tru bɔku bɔku rod dɛm. fכ egzampl, fכ ridyus di nכn-HDL-C, apoB, εn LDLP lεvεl dεm kin ridyus di risk fכ atεrosklεrosis; fכ ridyus di glycated hεmoglobin lεvεl kin impruv di bכdi glukכs kכntrכl pan pasεn dεm we gεt dayabitis, we de ridyus di risk fכ kכdivaskyul kכmplikεshכn dεm [3, 5, 6]..
Tritmεnt fכ nכn-alkoholik fεt liva sik (NAFLD): Retatrutid na nכvel tripl rεsεptכr agonist pεptida we de tכk to di glukagon rεsεptכr (GCGR), glukכs-dipεndεnt insulinotropik pכlipεptida rεsεptכr (GIPR), εn glukagon lεk pεptida-1 rεsεptכr (GLP-1R). Stɔdi dɔn sho se Retatrutid gɛt di potenshal fɔ trit nɔ-alkohol fat liva sik. Insay wan stכdi, dεn bin kכnεkt wan randomizεd, dכbl-blaynd, plasεbo-kכntrol trial fכ 48 wiks pan patisipan dεm wit mεtabolik disfכnkshכn-asכsiet fεt liva sik εn liva fεt kכntεnt ≥10%. di risal sho se na 24 wik, di avrej rilitiv chenj dεm na di liva fεt frכm di beslayn insay patisipan dεm we dεn trit wit difrεn doz dεm fכ Retatrutid (1mg, 4mg, 8mg, εn 12mg) na -42.9%, -57.0%, -81.4%, εn -82.4%, rispεktivli, we di wan na di plesibo grup na bin +0.3% [7] . Dis sho se Retatrutid kin gɛt impɔtant tritmɛnt ifɛkt pan nɔ-alkohol fat liva sik.
Fכ kכnklud, as nכvel tripl rεsεptכr agonist, Retatrutid sho big pכtεnshal fכ trit fכ fat εn sik dεm we de kכmכt frכm am. i kin rεgεl mכtalman mεtabolism frכm mכltipכl dimεnshכn dεm bay we i de aktibכt di glukagon rεsεpכta, glukכs-dipεndεnt insulinotropik polipεptida rεsεpכta, εn glukכs lεk pεptida-1 rεsεpכta, we de impruv di bכdi glukכs kכntrכl, ridyus di bכdi wet, εn rεgεl di lipid mεtabolism. Di we aw Retatrutid dɔn kam dɔn briŋ nyu tritmɛnt opshɔn fɔ di wan dɛn we fat, tayp 2 dayabitis mɛllitus, ɛn ɔda tin dɛn.Dɛn de op se i go brok di limiteshɔn dɛn we tradishɔnal singl riseptɔ agonist drɔgs gɛt, gi wan mɔ pawaful wɛpɔn fɔ sɔlv di prɔblɛm dɛn we de bɔku mɔ ɛn mɔ we gɛt fɔ du wit fat ɛn mɛtabolik sik dɛn, fɔ mek di divɛlɔpmɛnt go bifo pan di mɛdikal fild dɛn we gɛt fɔ du wit am, fɔ mek di kwaliti fɔ layf fɔ di sik pipul dɛn bɛtɛ, ɛn fɔ ridyus di soshal mɛdikal lod we dɛn kin du.
Bɔt di pɔsin we rayt di buk
Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.
Sayɛns Jɔnal Author
Rosenstock J na wan masta sabi bukman we gɛt bɔku pawa pan di mɛdikal fild, i de wok tranga wan wit institiushɔn dɛn lɛk di Yunivasiti ɔf Tɛksas Sawt Wɛstɛn Mɛdikal Sɛnta ɛn di Yunivasiti ɔf Tɛksas Dalas. I de du risach bak na sɛnta dɛn lɛk di Kanada VIGOR Senta ɛn Veloc Clin Res Ctr Med Siti.
In risach de span ɛndokrinɔlɔji ɛn mɛtabolism, kadiɔvaskyuɛl sistɛm ɛn kadyolɔji, famakɔlɔji, ɛn ɛkspirimɛnt mɛrɛsin, wit di fɔs tin we i de tɔk bɔt dayabitis, fat, ɛn tritmɛnt dɛn we gɛt fɔ du wit am ɛn divɛlɔpmɛnt fɔ drɔgs. J Rosenstock dɔn gɛt bɔku sakrifays pan klinik mɛrɛsin, we dɛn kɔl am Highly Cited Researcher frɔm 2017 to 2024. Dis de sho di ay impak ɛn bɔku pipul dɛn we dɛn no bɔt in wok. Tru kolaboreshɔn wit bɔku risach institiushɔn dɛm, i dɔn saksesful fɔ translet di bɛsis risach fayndin dɛm to klinik aplikeshɔn, bɛnifit pasɛnt dɛm wit mɛtabolik ɛn kadivaskyul sik dɛm ɛn advans mɛdikal sayɛns. Rosenstock J de list in di rεfrεns fכ saytεshכn [4].
